Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies to improve the lives of patients with immune-mediated diseases. The company's two lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory diseases and contribute to cytokine release by activating a broad range of inflammatory factors, including NF-κB, inflammasomes, and scavenger receptor A. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy.